198 related articles for article (PubMed ID: 314291)
1. Serum complement abnormalities in the antinuclear antibody-positive relatives of children with systemic lupus erythematosus.
Lehman TJ; Hanson V; Singsen BH; Kornreich HK; Bernstein B; King KK
Arthritis Rheum; 1979 Sep; 22(9):954-8. PubMed ID: 314291
[TBL] [Abstract][Full Text] [Related]
2. Correlation between the levels of antinuclear antibodies, anti-DNA antibodies, and complement in systemic lupus erythematosus.
Nguyen CP; Cao VV; Fehér J; Gergely P
Acta Med Hung; 1988; 45(2):145-59. PubMed ID: 3266790
[TBL] [Abstract][Full Text] [Related]
3. The association of antinuclear antibodies, antilymphocyte antibodies, and C4 activation among the relatives of children with systemic lupus erythematosus.
Lehman TJ; Curd JG; Zvaifler NJ; Hanson V
Arthritis Rheum; 1982 May; 25(5):556-61. PubMed ID: 6979340
[TBL] [Abstract][Full Text] [Related]
4. Complement split product C3d as an indicator of disease activity in systemic lupus erythematosus.
Röther E; Lang B; Coldewey R; Hartung K; Peter HH
Clin Rheumatol; 1993 Mar; 12(1):31-5. PubMed ID: 8467609
[TBL] [Abstract][Full Text] [Related]
5. Progressive reduction of serum complement levels: a risk factor for relapse in patients with hypocomplementemia in systemic lupus erythematosus.
Miyawaki Y; Sada K; Asano Y; Hayashi K; Yamamura Y; Hiramatsu S; Ohashi K; Morishita M; Watanabe H; Matsumoto Y; Kawabata T; Wada J
Lupus; 2018 Nov; 27(13):2093-2100. PubMed ID: 30309286
[TBL] [Abstract][Full Text] [Related]
6. Family study of systemic lupus erythematosus: analysis of the clinical history, skin immunofluorescence, and serologic parameters.
Lowenstein MB; Rothfield NF
Arthritis Rheum; 1977; 20(7):1293-1303. PubMed ID: 334183
[TBL] [Abstract][Full Text] [Related]
7. Relationship between anti-DNA antibodies complement consumption and circulating immune complexes in systemic lupus erythematosus.
Davis P; Cumming RH; Verrier-Jones J
Clin Exp Immunol; 1977 May; 28(2):226-32. PubMed ID: 301447
[TBL] [Abstract][Full Text] [Related]
8. The significance of serial measurements of serum complement C3 and C4 components and DNA binding capacity in patients with lupus nephritis.
Garin EH; Donnelly WH; Shulman ST; Fernandez R; Finton C; Williams RL; Richard GA
Clin Nephrol; 1979 Oct; 12(4):148-55. PubMed ID: 315852
[TBL] [Abstract][Full Text] [Related]
9. [Components of the classical complement pathway in systemic lupus erythematosus].
Maillet F; Goetz J; Hauptmann G; Clauvel JP; Mery JP; Kahn MF; Kazatchkine M
Presse Med; 1987 Mar; 16(8):378-82. PubMed ID: 2950498
[TBL] [Abstract][Full Text] [Related]
10. Relationship of clinical findings in systemic lupus erythematosus to seroreactivity.
Rothschild BM; Jones JV; Chesney C; Pifer DD; Thompson LD; James KK; Badger H
Arthritis Rheum; 1983 Jan; 26(1):45-51. PubMed ID: 6600613
[TBL] [Abstract][Full Text] [Related]
11. [Complement system in disseminated lupus erythematosus].
Vasquez JJ; Fontan G; Gil A; Barbado J; Alvarez I; Ojeda JA
Rev Rhum Mal Osteoartic; 1977 Dec; 44(12):725-31. PubMed ID: 76330
[TBL] [Abstract][Full Text] [Related]
12. Familial clustering of non-nuclear autoantibodies and C3 and C4 complement components in systemic lupus erythematosus.
Hunnangkul S; Nitsch D; Rhodes B; Chadha S; Roberton CA; Pessôa-Lopes P; Norsworthy PJ; Fernando MM; Charles P; Mackworth-Young C; Isenberg DA; Whittaker JC; Vyse TJ
Arthritis Rheum; 2008 Apr; 58(4):1116-24. PubMed ID: 18383369
[TBL] [Abstract][Full Text] [Related]
13. The significance of C3 and C4 complement levels in lupus nephritis.
Levo Y; Pick AI
Int Urol Nephrol; 1974; 6(3-4):233-8. PubMed ID: 4549215
[No Abstract] [Full Text] [Related]
14. [Optic immunofluorescence demonstration of monoclonal and polyclonal antinuclear antibodies (ANA) in rheumatoid arthritis (RA) and lupus erythematosus disseminatus (LED)].
Dreher R; Helmke K
Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():808-13. PubMed ID: 417508
[No Abstract] [Full Text] [Related]
15. The significance of serial measurement of serum anti-native DNA antibodies and complement C3 and C4 components in the management of patients with systemic lupus erythematosus.
Grennan DM; Moseley A; Sloane D; Pumphrey R; Dick WC; Buchanan WW
Aust N Z J Med; 1977 Dec; 7(6):625-9. PubMed ID: 306817
[TBL] [Abstract][Full Text] [Related]
16. Urine neopterin as a parameter of disease activity in patients with systemic lupus erythematosus: comparisons with serum sIL-2R and antibodies to dsDNA, erythrocyte sedimentation rate, and plasma C3, C4, and C3 degradation products.
Lim KL; Jones AC; Brown NS; Powell RJ
Ann Rheum Dis; 1993 Jun; 52(6):429-35. PubMed ID: 8323394
[TBL] [Abstract][Full Text] [Related]
17. Anti-CII antibody as a novel indicator to assess disease activity in systemic lupus erythematosus.
He C; Mao T; Feng Y; Song T; Qin C; Yan R; Feng P
Lupus; 2015 Nov; 24(13):1370-6. PubMed ID: 26048288
[TBL] [Abstract][Full Text] [Related]
18. The value of complement measurements in the assessment of lupus activity.
Milis L; Timmermans V; Morris CA; Pussell BA; Charlesworth JA
Aust N Z J Med; 1992 Aug; 22(4):338-44. PubMed ID: 1445021
[TBL] [Abstract][Full Text] [Related]
19. Immunological studies in systemic lupus erythematosus.
Jin OC; Jacob E; Chua D; Lan YS; Hsii FP
J Med Assoc Thai; 1978 Jan; 61 Suppl 1():10-7. PubMed ID: 304878
[No Abstract] [Full Text] [Related]
20. Serum complement values (C3 and C4) to differentiate between systemic lupus activity and pre-eclampsia.
Buyon JP; Cronstein BN; Morris M; Tanner M; Weissmann G
Am J Med; 1986 Aug; 81(2):194-200. PubMed ID: 3740078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
